Introduction {#sec1-0271678X18776820}
============

In the last decade, combined PET/CT demonstrated the added value of anato-metabolic imaging^[@bibr1-0271678X18776820]^ in patient management, mainly in oncology.^[@bibr1-0271678X18776820],[@bibr2-0271678X18776820]^ With the advent of combined PET/MR imaging, we witness a similar paradigm shift in managing patients with neurological disorders.^[@bibr3-0271678X18776820]^ Specifically, fully integrated PET/MRI bodes well for the prospect of finally realizing the promise of absolute quantification of PET data in clinical routine. This migration from semi-quantitative measures to full quantification is highly desirable as it has the potential to improve the diagnostic value of molecular imaging.^[@bibr4-0271678X18776820]^ To this end, routine quantification will depend on the development of automated approaches to provide clinicians with absolute quantitative values, in the same way as with standardized uptake values (SUVs) today.^[@bibr5-0271678X18776820]^

Absolute quantification in PET studies of the brain requires the knowledge of an input function (IF). In research studies, an arterial input function (AIF) can be obtained using arterial cannulation and collection of blood samples at regularly timed intervals. However, this approach is untenable for clinical routine. As a result, clinical brain studies currently apply a semi-quantitative approach based on SUVs, which lacks an absolute physiological scale. In the past, extraction of an IDIF for PET brain studies proved to be a challenge, given the presence of partial volume effects (PVEs)^[@bibr6-0271678X18776820],[@bibr7-0271678X18776820]^ and involuntary subject motion.^[@bibr6-0271678X18776820],[@bibr8-0271678X18776820]^

Various methodological approaches have been proposed to calculate an accurate IDIF, thereby accounting for the factors above. These methods can be classified into three categories: (1) PET-only,^[@bibr9-0271678X18776820][@bibr10-0271678X18776820][@bibr11-0271678X18776820][@bibr12-0271678X18776820][@bibr13-0271678X18776820][@bibr14-0271678X18776820][@bibr15-0271678X18776820][@bibr16-0271678X18776820][@bibr17-0271678X18776820][@bibr18-0271678X18776820]--[@bibr19-0271678X18776820]^ (2) standalone PET and MRI,^[@bibr20-0271678X18776820][@bibr21-0271678X18776820][@bibr22-0271678X18776820][@bibr23-0271678X18776820][@bibr24-0271678X18776820]--[@bibr25-0271678X18776820]^ and (3) combined PET/MRI.^[@bibr26-0271678X18776820][@bibr27-0271678X18776820][@bibr28-0271678X18776820]--[@bibr29-0271678X18776820]^ Most of the PET-only methods mandate the measurement of venous samples from a second venous line to avoid errors in IDIF originating from spill-in and spill-out effects occurring at late time points.^[@bibr6-0271678X18776820],[@bibr30-0271678X18776820]^ On the other hand, standalone PET- and MR-based methods are subject to logistical challenges and a sheer amount of post-processing required. A fully integrated PET/MRI addresses the main challenges for the determination of an accurate IDIF in a clinical setting, such as delineation of the internal carotid arteries^[@bibr20-0271678X18776820],[@bibr26-0271678X18776820],[@bibr27-0271678X18776820]^ and motion correction of dynamic PET frames using MR navigators.^[@bibr31-0271678X18776820]^

Here, we introduce an MR-driven approach that allows for an automated calculation of IDIF using the synergistic information from an integrated PET/MRI. The calculated IDIF then allows for the non-invasive determination of brain metabolic rate of glucose (CMRGlc). Specifically, we employ an automated vessel segmentation algorithm and a PVC method, which accounts for the radial and circumferential variability of the PET tracer distribution around the vessel. Our objective was to establish an automated workflow for the absolute quantification of \[18F\]FDG-PET/MRI brain data for clinical routine that is validated against the reference standard (AIF).

Materials and methods {#sec2-0271678X18776820}
=====================

Ten healthy adults ((27 ± 7) years, (70 ± 10) kg, 5 males and 5 females) were included in this study. The study was approved by the Ethics Committee of the Medical University of Vienna (EK1960/2014) and was performed in accordance with the Declaration of Helsinki (1964), including current revisions. Subjects were confirmed to be healthy based on medical history, physical examinations and vital signs. Written informed consent was obtained from all subjects prior to the examinations.

Imaging protocol {#sec3-0271678X18776820}
----------------

All subjects underwent test--retest PET/MRI brain examinations on a fully integrated PET/MRI system (Siemens Biograph mMR). All examinations were performed in the afternoon, with subjects at rest with their eyes open. Moreover, no specific task was performed by the subject. The average time difference between the two examinations was (17 ± 44) days. Prior to each scan, a venous line was established for the injection of the \[18F\]FDG tracer and an arterial line was established in the contralateral arm for blood sampling. A head and neck coil was used in order to ensure a high signal-to-noise ratio of the MR imaging. Foam cushions were placed inside the MR head coil to minimize involuntary head movement.

The integrated PET/MR imaging protocol included a 3D time-of-flight MR angiography (TOF-MRA) sequence to image the internal carotid arteries with the following parameters: 0.5 × 0.5 × 1 mm^3^ voxel size, TE = 3.6 ms, TR = 21 ms, 25° flip angle, 228 × 384 matrix, 220 slices and an acquisition time of 6 min. The field-of-view of the TOF-MRA extended from the circle of Willis (CoW) to 10 slices below the branching point of the internal and external carotid arteries (ECAs). Subsequently, subjects were injected with \[18F\]FDG ((352 ± 66) MBq, 5.18 MBq/kg) intravenously as a slow bolus over 40 s. At the start of the injection, a 60-min list mode PET data acquisition was initiated and blood samples (1mL each) were obtained from the radial artery using a varying time schedule (24 × 5 s, 1 × 60 s, 1 × 120 s, 1 × 300 s, 1 × 600 s, 2 × 1200 s post injection) (Supplementary Figure 1). The blood sampling was done manually using vacuum test tubes via an arterial cannula fitted with an adapter. Prior to every arterial sample, the line was flushed with 5 mL sodium chloride solution to prevent clotting and sampling stagnant blood. To avoid dilution of the actual sample, a 1 mL of discard was drawn followed by the sampling of arterial blood sample. Whole-blood radioactivity concentrations were measured using a gamma counter (PerkinElmer, 2480 Automatic Gamma counter, Wizard^[@bibr2-0271678X18776820]^3). To obtain the AIF, whole blood samples were centrifuged to separate the plasma component, followed by the measurement of radioactivity in the plasma. The measured whole blood and plasma tracer concentrations were used to calculate the dynamic plasma-to-blood ratio for each subject. This ratio was then used to convert the blood-IDIF to plasma-IDIF. Arterial sample concentrations were measured at instantaneous time-points, whereas the IDIF concentrations were measured at PET mid-scan time-points. In order to match the instantaneous blood sampling times with the PET mid-scan time, the AIF was interpolated into discrete time segments of 1 s length using a Piecewise Cubic Hermite Interpolating Polynomial.

To monitor head motion, MR navigators were used throughout the dynamic PET acquisition using the following parameters: 2D EPI 3.0 × 3.0 × 3.0 mm^3^ voxels, 64 × 64 matrix, 36 slices, TE 30 ms, TR 3000 ms. Navigator volumes were obtained at fixed time intervals: 0, 2.5, 5, 7.5, 10, 14, 17, 21, 26, 33, 38, 42, 44 and 50.5 min post injection. Following the PET/MRI examination, the subjects were moved to a PET/CT system (Biograph TruPoint64, Siemens Healthcare, USA), where a low-dose CT scan (120 kVp, 50 mAs) of the brain was acquired solely for the purpose of attenuation correction (AC).^[@bibr32-0271678X18776820],[@bibr33-0271678X18776820]^

The PET list mode data were re-binned into a dynamic frame sequence (24 × 5 s, 1 × 60 s, 1 × 120 s, 1 × 300 s, 1 × 600 s, 2 × 1200 s post injection) and each PET frame was reconstructed (Siemens e7 tools) into a 344 × 344 × 127 matrix (voxel size 2.08 × 2.08 × 2.03 mm^3^) using the ordinary Poisson ordered subset expectation maximization (OP-OSEM) 3D algorithm (3 iterations, 21 subsets, 2 mm Gaussian filter). Scatter correction along with a CT-AC was applied to all PET data.^[@bibr34-0271678X18776820]^ To perform the CT-AC, the low-dose CT scan was co-registered to the T1-MPRAGE sequence (RS-1, Supplementary Figure 1) and a bilinear scaling^[@bibr31-0271678X18776820]^ was applied to convert the low-dose CT image to a CT-AC map.

Automated ICA segmentation {#sec4-0271678X18776820}
--------------------------

Data from the 3D TOF-MRA sequence were used to extract the ICA. To obtain the IDIF, the petrous region of the ICA was chosen as the volume-of-interest (VOI). Image segmentation was performed in three steps:

### Extraction of the carotid vasculature {#sec5-0271678X18776820}

A combination of histogram-based quantile thresholding^[@bibr35-0271678X18776820],[@bibr36-0271678X18776820]^ and automatic seeded region growing was used to extract the entire carotid vasculature (CV) (Supplementary Figure 2). The intensity corresponding to the 0.987 quantile of the gray value distribution was chosen as the optimum threshold value following an iterative optimization procedure using the TOF-MRA datasets. To remove residual contributions of the peripheral fat, an automated seed region growing was performed with a connectedness constraint, yielding only the CV (Supplementary Figure 2).

### Extraction of the ICA {#sec6-0271678X18776820}

The obtained CV consists of the ICA, ECAs and the CoW (Supplementary Figure 2). The ICA was obtained by removing the CoW first, followed by the pruning of ECA. The CoW is superior to the cavernous segment and can be removed once the cavernous segment in the vasculature is localized. This was determined based on a morphological feature vector (Gz), which characterizes the shape of the vascular tree ([Figure 1](#fig1-0271678X18776820){ref-type="fig"}). This feature curve was calculated only for the intracranial segment of the TOF-MRA volume as only segmentation of the petrous part of the ICA was of interest. The morphological feature curve incorporates features, such as mean intensity, major axis length, ellipticity as well as the orientation of vessel segments present in the transaxial slices ([Figure 1](#fig1-0271678X18776820){ref-type="fig"}). The axial slice containing the structure with an orientation of 90° to the vessel denotes the location of the cavernous segment of the ICA, thus, allowing for the removal of the CoW. Moreover, the ICA and ECA arise from a common carotid artery, and therefore the localization of the branching point is key to the pruning of the smaller vessel (ECA), thus, leaving the ICA as the only remaining structure. Figure 1.Segmentation of the carotid vasculature (CV) features such as normalized mean intensity (Nz), major axis length (Mz) and ratio of major to minor axis length (Rz) were calculated and combined to produce a morphological feature vector (Gz), to highlight elliptical structures. The global maxima, Max~1~ of Gz (blue), corresponds to the petrous segment, while Max~2~ and Max~3~ correspond to the floor of circle of Willis (red) and cavernous (orange).

### Segmentation of the petrous region of the ICA {#sec7-0271678X18776820}

This segmentation was done based on the classification of ICA by Gibo et al.^[@bibr37-0271678X18776820]^ The feature curve in [Figure 1](#fig1-0271678X18776820){ref-type="fig"} highlights elliptical structures in the image as prominent peaks. Accordingly, the petrous segment was identified as the structure with the highest peak. These steps resulted in a petrous mask (P~mask~), which was later used to extract the IDIF from the dynamic PET frames.

PET motion correction and alignment with TOF-MRA {#sec8-0271678X18776820}
------------------------------------------------

To achieve the spatial correspondence between the PET frames and the MR-derived petrous masks, a post-reconstruction motion correction was employed. MR navigators interleaved between MR clinical sequences were used to monitor subject head motion (Supplementary Figure 1). The MR navigator acquired at the start of the PET acquisition (Nav-0, t = 0) was considered as the reference volume and all subsequent navigators were rigidly co-registered to Nav-0 (SPM 12, Wellcome Trust Center for Neuroimaging, UCL) to obtain the motion vectors. The resulting motion profile consisted of six parameters (three translations and three rotations; [Figure 2](#fig2-0271678X18776820){ref-type="fig"}). In early PET frames with low tracer activity, MR based motion correction was implemented. Temporal matching of MR navigators with PET frames was achieved using the least time difference between the PET frame mid-scan times and the navigator acquisition times. ([Figure 3(a)](#fig3-0271678X18776820){ref-type="fig"}). Eventually, transformation matrices obtained from the early MR navigators (\<10 min) with respect to the reference MR navigator will be applied to P~mask~, thus, generating multiple resliced P~mask~ VOIs. Figure 2.Translation (left) and rotation (right) profiles in each axis with respect to examination time (Supplementary Figure 1) for 20 datasets. Subject motion (translation and rotation) increased with time and subject translation was prominent in the z-axis. It is seen that the motion was minimal during the first 10 min of the scan (maximum translation \< 2 mm, average rotation \< 1 and maximum rotation \< 2°). Figure 3.(a) Use of MR navigator-based motion correction, in early PET frames (\<10 min). Each MR navigator is assigned to a PET frame based on the time difference between the PET frame midpoint (PFM, red) and MR navigator\'s acquisition time (AT). Lower the time difference between PFM and AT, higher the probability of assigning the MR navigator to the respecting PET frame. The MR navigator acquired at start of the PET acquisition (time = 00:00) is considered as the reference volume (RV) and all other MR navigators (02:30, 05:15, 07:30) are registered to RV. The transformation matrices obtained from the process are transferred to the 3D TOF-MRA or P~mask~, to achieve spatial correspondence to the PET frames. (b)Motion vectors (T~n~) were obtained by co-registering the TOF-MRA with the late dynamic PET frames (\>10 min) and then applied to the petrous mask (P~mask-n~) to achieve spatial correspondence with the late dynamic PET frames.

Subsequently, spatial correspondence between the petrous mask and the PET data (\>10 min) was achieved in a multi-step process using SPM 12 ([Figure 3(b)](#fig3-0271678X18776820){ref-type="fig"}). First, transformation matrices (T~10--60~) were derived from rigid inter-modality co-registration (Normalized mutual information) of the TOF-MRA data and the late PET frames (10 min, 20 min, 40 min and 60 min). Second, these matrices (T~10-60~) were applied to the petrous mask (P~mask~). The alignment was confirmed visually using AMIDE 1.0.5 (AMIDE\'s a Medical Image Data Examiner^[@bibr38-0271678X18776820]^) without the need for further post-processing.

As a part of quality control, MR navigators acquired after 10 min were used to check for intra-frame motion within the individual late PET image volumes (1 × 10 min, 2 × 20 min frames). Here, motion vectors never exceeded 1 mm in any direction (Supplementary Table 1), thus, indicating no prominent intra-frame motion.

Partial volume correction {#sec9-0271678X18776820}
-------------------------

Correction of PVE was performed using a modified version of the Mueller-Gaertner method (MGM),^[@bibr39-0271678X18776820]^ with the extension of accounting for radial and circumferential variability of the activity in the petrous segment\'s background. Calculation of the true ICA tracer concentration entails first the removal of variable background activity that spilled into the target region (spill-in correction) followed by correction of activity loss in the target region (spill-out correction) caused by the convolution of true activity distribution by the system\'s PSF. This procedure mandates the knowledge of both the PSF and the nature of the background activity distribution (Supplementary Figure 3).

In order to determine the PSF corresponding to the applied acquisition protocol, a 1-mL syringe (diameter 4.7 mm, cylinder length 57 mm) was filled with about 75 MBq of \[18F\]FDG and placed axially in the system in approximately the same off-center position (∼50 mm) as the presumed position of the ICA. Data were acquired and reconstructed using the same protocol as used in the subjects. Subsequently, a modeled profile (using a step function with a height corresponding to the tracer concentration in the syringe at the start of the PET scans) was convolved with a 3D Gaussian PSF and compared to the measured trans-axial profile. The FWHM of the PSF was incremented in 0.5 mm steps. The convolved model function that best approximated the measured profile defined the FWHM of the PSF corresponding with our protocol. The FWHM of the PSF for the PET/MR system in use (Biograph mMR) was found to be (6.0 ± 0.4) mm.

To obtain an initial estimate of background activity, the spill-out zone (Sp~out~) was defined by convolving P~mask~i~~ (*i* -- indicates the PET frame, with '*i*' varying from 1 to 30) with the derived PSF of the PET system ([Figure 4(a)](#fig4-0271678X18776820){ref-type="fig"}). An initial background mantel (B~mask~i~~) was defined 10 mm radially from the edges of the SPout ([Figure 4(a)](#fig4-0271678X18776820){ref-type="fig"}). To account for circumferential differences in background activity ([Figure 4(b)](#fig4-0271678X18776820){ref-type="fig"}), the tracer concentration in the ring-like structure was segmented into 20 background regions (B~mask~ij~~) by applying Otsu thresholding^[@bibr40-0271678X18776820]^ and scaled with the corresponding median activity (B~ij~) sampled from the PET frame. This allowed for the calculation of an initial estimate of ICA~i~ using equation(2), assuming that the area between each B~mask~ij~~ and the ICA wall contains a constant tracer concentration equal to the B~ij~ values determined at the periphery. $$\begin{matrix}
{\mathit{PE}T_{i} = (\mathit{IC}A_{i}.P_{\mathit{mask}_{i}}) \otimes \mathit{PSF}} \\
{+ \sum\limits_{j = 1}^{20}B_{\mathit{ij}}.B_{\mathit{mask}_{\mathit{ij}}} \otimes \mathit{PSF}} \\
\end{matrix}$$ $$\mathit{IC}A_{i} = \lbrack SP_{\mathit{Ou}t_{i}}\rbrack^{- 1}\lbrack\mathit{PE}T_{i} - \sum\limits_{j = 1}^{20}B_{\mathit{ij}}.SP_{in_{\mathit{ij}}}\rbrack$$ $$\begin{matrix}
{\text{~where~}\quad SP_{\mathit{ou}t_{i}} = P_{\mathit{mask}_{i}} \otimes \mathit{PSF}\text{~and~}SP_{in_{\mathit{ij}}}} \\
{= B_{\mathit{mask}_{\mathit{ij}}} \otimes \mathit{PSF}} \\
\end{matrix}$$ Figure 4.(a)Spill-in correction: automatic delineation of a spill-out region (SP~out~, orange), defined by convolving the petrous mask (P~mask~, red) with the PSF (FWHM-6.00 mm), and a background region (purple) of 10 mm (∼ 5 voxels) thickness defined from the edges of the spill-out region. (b) The circumferential heterogeneity of petrous segment (red) is graphically represented by labels (L~1−n~) with different colors, where *n* = 20. The radial heterogeneity is depicted using the sector-*n*, where the activity, M~n~ in the spill-out zone/mixed-zone (orange) is not the same as the activity, L~n~ in the background region (green).

Radial variability in the area between *B*~*mask~ij~*~ and *ICA* wall was addressed as follows. Initially, for each of the *B*~*mask~ij~*~ regions, a mixed zone (*MZ*~*ij*~) was defined, which includes the area between the *ICA* (*P*~*mask*~) and *B*~*mask~ij~*~ ([Figure 4(b)](#fig4-0271678X18776820){ref-type="fig"}). The true tracer concentration in *MZ*~*ij*~ (denoted *A*~*MZ~ij~*~) was then modelled as $$A_{Mz_{\mathit{ij}}} = \mathit{PE}T_{MZ_{\mathit{ij}}} - \mathit{ICA}.SP_{\mathit{ou}t_{i}} - B_{\mathit{ij}}.SP_{in_{\mathit{ij}}}$$ where *PET*~*MZ~ij~*~ is the observed tracer concentration in *MZ*~*ij*~ and *SP*~*in*~, the spill-in factor. Subsequently, the set of background regions was tested for radial homogeneity by calculating the differences between *A*~*MZ~ij~*~ and *B*~*ij*~. If *A*~*MZ~ij~*~ was found to be within 3% of *B*~*ij*~ (equivalent to \| *B*~*ij*~ -- *A*~*MZ~ij~*~ \| \< 0.03 *B*~*j*~), it was assumed that radial uniformity was met for that particular background segment. Otherwise, a new estimate of ICA was derived iteratively until equation (2) was satisfied: $$|\alpha_{\mathit{ij}} - \mathit{ICA}.SP_{\mathit{ou}t_{i}}| = \text{min}$$ $$\alpha_{\mathit{ij}} = (\mathit{PE}T_{MZ_{\mathit{ij}}} - B_{\mathit{ij}}.SP_{in_{\mathit{ij}}} - A_{MZ_{\mathit{ij}}})$$ where α~*ij*~ is the observed spill-out contribution in the mixed zone *MZ*~*ij*~ originating from the true ICA tracer concentration.

Here, the difference between the observed (α~ij~) and modeled (*ICA* × *SP*~*out*~) ICA spill-out contribution in *MZ*~*ij*~ was minimized for the whole set of mixed zones (MZ~ij~, j = 1,...20). The resulting ICA value was adjusted for maximum agreement of radial profiles in the mixed zone, thus, accounting for radial inhomogeneity. This procedure was repeated for all PET frames, to generate a partial volume corrected IDIF. Supplementary Figure 4 summarizes the radial and circumferential variability in a real case scenario.

Post-processing of the IDIF {#sec10-0271678X18776820}
---------------------------

Following MoCo and PVC, the IDIF was interpolated with a step length of 1 s to match the blood sampling times and was corrected for multiple effects. First, a plasma IDIF was derived based on the individual plasma-to-blood ratios obtained from sampled arterial blood of the study subjects. Second, the IDIF was scaled using the cross-calibration factor between the PET/MR and the on-site gamma counter. Third, the delay between the AIF and the IDIF was corrected by shifting the IDIF curve to match the arrival times of the AIF. Finally, due to the difference in sampling location (ICA for IDIF and radial arteries for AIF), a mono-exponential dispersion function with a tau value of 5 s^[@bibr41-0271678X18776820],[@bibr42-0271678X18776820]^ was convolved with the IDIF to mimic the dispersion effects. Since the AIF is considered as the reference standard, all the corrections were applied to the IDIF for an unbiased comparison with the AIF.

Assessment of IDIF-derived metabolic rate of glucose {#sec11-0271678X18776820}
----------------------------------------------------

To assess agreement between the IDIF and AIF, the area-under-the-curve (AUC) derived from both curves was used. Specifically, disparities between the AUC measurements were assessed based on the percentage AUC difference (%Diff~AUC~) calculated as $$\%\text{Dif}\text{f}_{\text{AUC}} = 100(\text{AU}\text{C}_{\text{AIF}} - \text{AU}\text{C}_{\text{IDIF}})/(\text{AU}\text{C}_{\text{AIF}})$$

Absolute percentage AUC differences were calculated across all studies as well as pair-wise between test and re-test acquisitions.

Finally, cerebral metabolic rate of glucose (CMRGlc) maps were calculated (PMOD 3.802, PMOD Technologies, Zurich, Switzerland) using the standard rate constant approach^[@bibr43-0271678X18776820]^ (lumped constant, LC = 0.65^[@bibr61-0271678X18776820]^). Absolute percentage differences between regional CMRGlc values for whole brain and in six pre-selected large regions of the brain (cerebellum, brainstem, anterior cingulate cortex, thalamus, corpus callosum and superior frontal cortex) from the Hammersmith atlas were determined using AIF and IDIF. All comparisons were performed in a non-parametric manner, using the median difference, the interquartile range and the extremes. In order to determine whether regions are affected differentially using the IDIF, a rank-sum test was performed among all regions.

Test--retest variability for both the IFs was assessed by calculating the absolute mean % difference, after normalizing the IFs to the respective injected dose and body weight (SUV). Similarly, test--retest variability was assessed by calculating the absolute median % difference for the CMRGlc values (whole brain and four random regions -- insula, caudate, mid-frontal gyrus and superior frontal gyrus) obtained from both IFs

Results {#sec12-0271678X18776820}
=======

Assessment of the percentage difference between all AUCs using the IDIF and AIF yielded values within ±5% ([Figure 5(a)](#fig5-0271678X18776820){ref-type="fig"}), with a median absolute difference of 2.5% (interquartile range (IQR) = 2%--4%). [Figure 5(b)](#fig5-0271678X18776820){ref-type="fig"} shows the histogram of the absolute percent differences, indicating that 14/20 (70%) of the IDIF curves were found to be within 3% of the reference standard (AIF). The remaining 30% displayed a somewhat larger AUC difference in the range of 3%--5%. Moreover, 2/3 of all percent differences were determined to be positive, indicating a trend towards a possible overestimation of the AUC using the IDIF. The representative time-activity curves emphasizing the relationship between arterial blood samples and the IDIF are shown for a case with AUC difference \<3% ([Figure 5(c)](#fig5-0271678X18776820){ref-type="fig"}) and for a case with AUC difference ∼4% ([Figure 5(d)](#fig5-0271678X18776820){ref-type="fig"}). Figure 5.(a) The panel displays the %-differences for all 20 scans (points); the shaded areas depict the difference range for test/retest scans obtained in the same subject. IDIF curves obtained from subject \#5 (HC004 test, denoted as \*) and \#9 (HC007 test, denoted as \*\*) are displayed in (c) and (d). Percent (%) differences between AUCs obtained from AIF (gray with circles) and IDIF (black) were calculated (b). Histogram displaying the distribution of absolute % AUC differences, 70% of the AUCs differ by \<3% with the remaining curves differing by \<5%. (c) IDIF obtained in subject \#5: (HC004 test [Table 1](#table1-0271678X18776820){ref-type="table"}) with a good agreement between IDIF and AIF. (d) Example IDIF obtained from subject \#9 (HC007 test) with a limited (tail area) agreement between IDIF and AIF. Table 1.Demographics of the 10 healthy controls.Subject IDGenderAge (y)Weight (kg)DateFDG Activity (MBq)Blood glucose (mmol/L)TestRetestTestRetestTestRetestHC002M237506-06-201614-07-20162173714.555.72HC003F245508-06-201609-11-20162292884.334.73HC004M287411-07-201626-09-20163843674.885.49HC006F226912-09-201607-11-20163653555.115.22HC007F225614-09-201628-09-20162922925.385.61HC009F426323-11-201605-12-20163303245.115.83HC010F206507-12-201619-12-20163373385.115.55HC012M369223-01-201713-02-20174934766.326.05HC013M247015-02-201727-02-20173503635.055.16HC014M258027-03-201729-03-20174223644.615.88

Supplementary Figure 5 depicts the range of the AUCs for AIF (46.2 ± 7.6), IDIF with PVC (46.4 ± 8.1) and IDIF without PVC (35.7 ± 7). Supplementary Figure 6 shows the test--retest variability in the IFs, both AIF and IDIF showed similar variability with an absolute mean % difference (test--retest) of 9 ± 8% and 9 ± 7%.

[Figure 6(a)](#fig6-0271678X18776820){ref-type="fig"} shows an example of a parametric image based on AIF and IDIF for a subject (HC014 retest) with 3% overestimation by IDIF. The whole brain CMRGlc values derived from AIF was found to be (mean ± SD = 32 ± 6, median ± IQR = 31 ± 9) umol/100 g/min and for IDIF (mean ± SD = 32 ± 6, median ± IQR = 29 ± 9) umol/100 g/min (Supplementary Figure 10). Absolute median % difference between CMRGlc values obtained using the AIF and IDIF for the whole brain was found to be 3.9%, with an interquartile range of 2.4%--5.4%. And for the six regions, the absolute mean % difference was determined as 3.2%, with an interquartile range of 2.4%--4.3% and a maximum difference of \<10%. [Figure 6(b)](#fig6-0271678X18776820){ref-type="fig"} shows the %-differences with respect to CMRGlc values derived using the two IFs. Comparison of [Figures 5(c)](#fig5-0271678X18776820){ref-type="fig"} and [6(b)](#fig6-0271678X18776820){ref-type="fig"} indicates an inverse relationship between the percentage difference in AUCs and CMRGlc. Figure 6.(a) Transaxial (top row) and sagittal (bottom row) images representing CMRGlc derived using the AIF (left) and the IDIF (right) for a subject with a 3% AUC overestimation by IDIF. Images show excellent agreement in absolute CMRGlc values. (b)Relative %-differences for six reference regions (cerebellum, brainstem, anterior cingulate cortex, thalamus, corpus callosum and superior frontal cortex) in all 20 scans. The shaded areas depict test/retest scans obtained in the same subject. (c)Histogram depicting the % absolute differences in CMRGlc values derived using the IDIF and the AIF. The graph shows a maximum for difference values in the range of 2--4%, with 85% of all differences laying within 5%.

[Figure 6(c)](#fig6-0271678X18776820){ref-type="fig"} shows the corresponding histogram, indicating that the most frequently observed differences are in the range of 2%--4%, with 85% of all differences being \<5%. In all six-preselected brain regions, the CMRGlc values obtained from AIF and IDIF showed no significant difference.

The test--retest variability between AIF based CMRGlc and IDIF based CMRGlc is shown in Supplementary Figure 7. For both the IFs, CMRGlc obtained from the four regions during the retest were higher when compared to test, along with a reduction in variance during the retest. In general, retest AIF CMRGlc values were 14% higher (14% higher for insula, mid-frontal gyrus, superior frontal gyrus and 22 % higher for caudate) when compared to the test values, indicating a high intra-variability. A similar tendency was seen in retest IDIF CMRGlc values as well, with a 17% increase (12% higher for insula, 18% for caudate, 17% for mid-frontal gyrus and 16% for superior frontal gyrus) when compared to test values.

The absolute % relative difference between test and retest whole-brain CMRGlc values (Supplementary Figure 11) was found to be 14 ± 8% for AIF (with median ± IQR = 15 ± 16%) and 15 ± 10% for IDIF (with median ± IQR = 14 ± 17%).

Discussion {#sec13-0271678X18776820}
==========

We present a clinically viable automated MR-driven approach to extracting an IDIF for the non-invasive determination of CMRGlc images using an integrated \[18F\]FDG-PET/MRI protocol. The approach is based on the accurate and automated extraction of an IDIF based on the combined acquisition of PET and MR data. It was validated against the reference standard of AIF. In the context of the automated IDIF calculation, a multi-factorial partial volume correction is required. Therefore, the directional and radial variability of the background region ([Figure 4(b)](#fig4-0271678X18776820){ref-type="fig"}) must be considered for an accurate correction of the spillover effects. This procedure also mandates the knowledge of the system\'s PSF for a given tracer and image reconstruction protocol. Any PVC must be preceded by motion correction. Our study shows that the above requirements can be effectively addressed by employing an integrated PET/MRI protocol followed by an automated post-processing pipeline.

Traditionally IDIF has been extracted from two different segments of the ICA: (1) the petrous region^[@bibr24-0271678X18776820][@bibr25-0271678X18776820][@bibr26-0271678X18776820]--[@bibr27-0271678X18776820],[@bibr29-0271678X18776820],[@bibr44-0271678X18776820][@bibr45-0271678X18776820]--[@bibr46-0271678X18776820]^ or (2) the cervical region.^[@bibr20-0271678X18776820],[@bibr47-0271678X18776820]^ We believe that the petrous region is preferable, as it represents a rigid structure due to its placement inside the petrous canal. In contrast, the cervical segment is more elastic and prone to deformation. Since rigid transformations were used to achieve spatial correspondence between the TOF-MRA and the PET frames, the petrous region was chosen for derivation of the IDIF. The aforementioned segmentation algorithm was successful in defining the ICA irrespective of the subject-specific cerebral vasculature (Supplementary Figure 1). Moreover, due to its modular nature, the proposed algorithm can be easily modified for other FOV acquisitions (cervical and cavernous segments). The optimum quantile value of 0.987 may change based on the quality of TOF-MRA volumes. Decreasing the quantile value will result in higher inclusion of peripheral fat, whereas an increase will result in eroded segmentation of the carotid arteries. Care should be taken in choosing an optimum quantile value as the pre-segmentation of the carotid arteries is dependent on the chosen quantile value.

The ICA has a variable background both in radial and circumferential direction. Circumferential variability is due to the presence of cortical structures with different amount of tracer accumulation around the target region, whereas radial variability is related to the sampling of the background region ([Figure 4(a) and (b)](#fig4-0271678X18776820){ref-type="fig"}). Due to the spillover of ICA activity into the neighboring background tissue, an estimate of the circumferentially dependent background tracer concentration must be obtained at a distance from the ICA where the ICA spillover can be ignored. In most implementations, this is achieved by sampling background tracer concentration at a distance where ICA tracer concentration contributes \<3% to the local tracer concentration. Of note, this approach cannot account for radial changes, as the tracer concentration sampled in such a way might not be representative for the background concentration directly adjacent to the vessel wall (Supplementary Figure 4).

The importance to account for radial and circumferential variability has not been fully appreciated in previous region-based PVC methods. Rousset et al.^[@bibr48-0271678X18776820]^ derived a closed solution for PVC using a geometric transfer matrix, which relates a vector of observed activities to a vector of true (PVC-corrected) activities. This linear equation system can be solved for the true activities by matrix inversion; however, the accuracy of such a solution strongly depends on the degree of ill-conditioning of the transfer matrix and, in addition to a large computational effort, might lead to unstable estimates of the corrected activities.

Obviously, the complexity of such a correction is dependent on the number of tissues believed to have different functional properties, i.e. the number and shape of homogenous regions that contribute to the PVE in each image voxel. Various investigators proposed the definition of such regions based on a combination of information from a high-resolution anatomical (e.g. MRI) and a functional (PET) image using wavelet decomposition.^[@bibr49-0271678X18776820],[@bibr50-0271678X18776820]^ Our approach is similar to these methods in that it uses functionally homogenous background regions to correct for PVEs at one specific target region (ICA). Furthermore, it is accurate and computationally efficient for determining an IDIF by avoiding complex mathematical overhead by iteratively adjusting the activity in the target region so that it becomes consistent with the observed activity in the mixed zone. Although our approach is less ambitious than the general solution presented by Roussett et al., we believe that it is fitting for determining an IDIF that can be readily implemented in clinical applications.

The proposed PVC method requires the knowledge of PSF of the PET system. Since PSF varies with factors such as image reconstruction parameters and the type of tracer, a dedicated PSF measurement for the specific PET system and protocol is recommended.

Since all corrections are applied to a relatively small region, determination of an IDIF is highly sensitive to local misregistration arising from involuntary patient motion (Supplementary Figure 8). In a combined PET/MR system, MR navigator sequences can be used to derive high-temporal-resolution motion estimates along with the PET emission scan.^[@bibr31-0271678X18776820]^ The resulting motion vectors can be then applied to the VOI to account for motion between frames, therefore, avoiding PET image resampling. In the current protocol, MR navigators were acquired with a reasonably fast temporal sampling rate (∼2 min temporal separation between navigator), during the early phase of the scan (\<10 min), thereby offering the possibility to perform motion correction using the motion fields from the MR navigators. However, due to the constraints of clinical sequences during the subsequent 50 min, MR navigators were acquired with low-temporal sampling rate (∼4--5 min temporal separation between every navigator). Therefore, a PET-MRI NMI-based co-registration was preferred, instead of using the motion fields from the late navigators (\>10 min). Since MR navigators are acquired in a relatively short time duration (∼5 s), there is an increased probability that the motion vectors captured by these navigators are not representative of the average motion occurring during a 5-min time frame. While post-reconstruction motion correction approaches yield satisfactory results, simultaneously acquired PET and MR data offer the possibility of an "on-the-fly" motion correction, in which the motion vector is used to rebin the PET coincidence data, so that subject motion is addressed on a very basic line-of-response (LOR) level. Several pilot approaches have been proposed to incorporate on-the-fly motion correction schemes,^[@bibr51-0271678X18776820]^ yet implementation of these methods proved to be challenging due to the necessity of recalculating both normalization factors and random estimates.

Apart from comparing the CMRGlc images from the AIF and IDIF to determine the accuracy of the IDIF methodology, it is informative to compare the IFs by using metrics such as AUC. In the context of the standard rate constant approach, the AUC of the IF represents the total amount of tracer that is available to the tissue, while the metabolic rate encodes the relationship between the amount of tracer available for uptake and the actual tissue uptake. Therefore, demonstration of similarity by comparing the AUCs of AIF and IDIF provides a reasonable quality check to assess the accurateness of the method.

Analysis of AIF-derived AUC differences obtained from test/retest scans showed no significant correlation between the AUC differences and the length of time separating the two acquisitions (R^2^ = 0.03). These results suggest that time effects are most likely not responsible for the observed differences in IDIF-derived AUCs determined for the test/retest studies. A high test-retest variability ( \< 20%) was seen in regional CMRGlc obtained from both the IFs (Supplementary Figure 7). A regional analysis of CMRGlc was chosen, as studies in the past have indicated the possibility of different brain regions exhibiting different amount of metabolic variability.^[@bibr52-0271678X18776820],[@bibr53-0271678X18776820]^ However, it has been hypothesized that this relatively high amount of regional variability is due to changes in the physiological state of the subject across time.^[@bibr54-0271678X18776820][@bibr55-0271678X18776820][@bibr56-0271678X18776820]--[@bibr57-0271678X18776820]^

A current limitation of our study in view of a fully automation of the workflow is the need for a separate low-dose CT scan for CT-AC, which, for brain research, still is assumed a "silver standard."^[@bibr34-0271678X18776820]^ Various accurate brain MR-based attenuation correction (MR-AC) methods^[@bibr58-0271678X18776820]^ have been proposed in the recent years and there is now guarded optimism in the field that, at least for the brain, MR-AC will soon be clinically feasible.^[@bibr32-0271678X18776820],[@bibr33-0271678X18776820]^ However, the impact of these methods with respect to the derivation of an accurate IDIF still needs to be investigated. In our current study, the observed motion was minimal (maximum translation \< 2.0 mm and maximum rotation \< 2.0°, [Figure 2](#fig2-0271678X18776820){ref-type="fig"}) for all subjects during the first 10 min of the study. Therefore, no motion correction was performed for the early PET frames (\<10 min). Though, a practical MR navigator-based motion correction approach^[@bibr31-0271678X18776820]^ was implemented ([Figure 3(a)](#fig3-0271678X18776820){ref-type="fig"}) to handle prominent motion for early PET frames (\>2 mm), the performance of the method still needs to be evaluated. In our current implementation, stationary attenuation maps were used to perform AC, as motion magnitudes were minimal. However, such an approach might not be optimal in a clinical scenario where motion can be prominent. Since, CT-AC map misalignments can affect the quantification of the IDIF, the use of motion corrected CT-AC maps to reconstruct clinical PET data is advisable.

Finally, the calculation of CMRGlc was based on the standard rate constant approach since this study was performed with healthy volunteers. Though the use of standard rate constants might be less accurate than the application of kinetic modeling in case of pathology, the simplified approach might be better suited for clinical routine. Furthermore, when adopting our approach for the clinic, the obtained blood IDIF needs to be converted to plasma IDIF by using the hematocrit measured from the venous blood. However, it has been shown that the hematocrit values obtained from venous blood are ∼3% higher than those obtained from arterial blood^[@bibr59-0271678X18776820]^ and this difference must be considered during the conversion. In our study, we used the individual dynamic plasma to whole blood ratio to derive the plasma-IDIF. The mean (±SD) of this ratio derived from our study group (n = 20) was found to be 1.06 ± 0.01 (Supplementary Figure 9). Therefore, in future \[18\]FDG studies without arterial blood samples, we intend to apply a scaling factor of 1.06 to convert the blood-IDIF to plasma-IDIF.

As discussed earlier, most PET-based methods^[@bibr9-0271678X18776820][@bibr10-0271678X18776820][@bibr11-0271678X18776820][@bibr12-0271678X18776820][@bibr13-0271678X18776820][@bibr14-0271678X18776820][@bibr15-0271678X18776820][@bibr16-0271678X18776820][@bibr17-0271678X18776820][@bibr18-0271678X18776820]--[@bibr19-0271678X18776820]^ require blood samples for scaling the IDIF, while the stand-alone PET/CT and MR-based methods^[@bibr20-0271678X18776820][@bibr21-0271678X18776820]--[@bibr22-0271678X18776820]^ suffer logistic and co-registration issues. Integrated PET/MR-based IDIF methods,^[@bibr27-0271678X18776820],[@bibr60-0271678X18776820]^ apart from providing logistic advantage, have shown to be promising in addressing the challenges associated with the calculation of IDIF. Our method extends the previous PET/MR approaches, by introducing an FOV independent robust petrous segmentation algorithm, MR navigator-based motion monitoring and a PVC algorithm, which accounts for circumferential and radial homogeneity for spill-in correction.

Conclusion {#sec14-0271678X18776820}
==========

We have developed a computational framework to automatically calculate an IDIF for the absolute quantification of \[18F\]FDG PET brain data using a fully integrated PET/MRI system. Calculations of the IDIF and the CMRGlc parameters have been shown to correspond well to the values derived from the invasive AIF, thus, attesting to the concept of non-invasive absolute quantification of \[18F\]FDG PET imaging of the brain in combined PET/MRI studies.
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